Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.

about

Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.

Item

http://www.wikidata.org/entity/Q40612189

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Immunological evaluation of pe ...... inoma of unknown primary site.

@en

type

Item

label

Immunological evaluation of pe ...... inoma of unknown primary site.

@en

prefLabel

Immunological evaluation of pe ...... inoma of unknown primary site.

@en

P1476

Immunological evaluation of pe ...... inoma of unknown primary site.

@en

P2093

Akira Yamada

http://www.w3.org/2001/XMLSchema#string

Kyogo Itoh

http://www.w3.org/2001/XMLSchema#string

Masanori Noguchi

http://www.w3.org/2001/XMLSchema#string

Michi Morita

http://www.w3.org/2001/XMLSchema#string

Shigeki Shichijo

http://www.w3.org/2001/XMLSchema#string

Shigeru Yutani

http://www.w3.org/2001/XMLSchema#string

Shinjiro Sakamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.

Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial

Carcinomas of an unknown primary origin--diagnosis and treatment.

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.

Cancer of unknown primary site.

Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.

Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.

An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.

Differential expression of two classes of lck transcripts upon phorbol ester treatment of human leukemic T cells.

P2888

s00262-016-1887-5

P304

1223-1231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-016-1887-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046023171

http://www.w3.org/2001/XMLSchema#string

P698

27549314

http://www.w3.org/2001/XMLSchema#string

P921

immunology